Zymeworks Operating Income 2016-2022 | ZYME
Zymeworks operating income from 2016 to 2022. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Zymeworks Annual Operating Income
(Millions of US $) |
| 2021 |
$-216 |
| 2020 |
$-187 |
| 2019 |
$-151 |
| 2018 |
$-33 |
| 2017 |
$-9 |
| 2016 |
$-38 |
| 2015 |
$-20 |
Zymeworks Quarterly Operating Income
(Millions of US $) |
| 2022-06-30 |
$-66 |
| 2022-03-31 |
$-73 |
| 2021-12-31 |
$-41 |
| 2021-09-30 |
$-61 |
| 2021-06-30 |
$-69 |
| 2021-03-31 |
$-45 |
| 2020-12-31 |
$-38 |
| 2020-09-30 |
$-74 |
| 2020-06-30 |
$-40 |
| 2020-03-31 |
$-36 |
| 2019-12-31 |
$-74 |
| 2019-09-30 |
$-34 |
| 2019-06-30 |
$-29 |
| 2019-03-31 |
$-15 |
| 2018-12-31 |
$8 |
| 2018-09-30 |
$-20 |
| 2018-06-30 |
$-2 |
| 2018-03-31 |
$-20 |
| 2017-12-31 |
$33 |
| 2017-09-30 |
$-17 |
| 2017-06-30 |
$-9 |
| 2017-03-31 |
$-16 |
| 2016-12-31 |
$-11 |
| 2016-09-30 |
$-11 |
| 2016-06-30 |
$-7 |
| 2016-03-31 |
$-10 |
| 2015-12-31 |
|
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.619B |
$0.027B |
|
Zymeworks Inc. is a clinical-stage biopharmaceutical company. It engages in the discovery, development, and commercialization of bio-therapeutics for the treatment of cancer in Canada. The companys lead product candidate includes ZW25 and ZW33 which are in clinical trial stage. Zymeworks Inc. is headquartered in Vancouver, Canada.
|
